It has been reported that NSCLC patients with EGFR mutation may possibly benefit from combined immunotherapy.[15] But a significant proportion of patients still suffer from disease progression.[16] In our case, the efficacy of the second-line immunotherapy combined with chemotherapy treatment was assessed as PR after 3 months before disease progression. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.